“Sanofi-aventis at a glance” brochure

Sanofi-aventis
at a glance

Thomas Barwick / Digital Vision / Getty Images

Strengthening life,
everywhere
A complete range of
products and a regional
approach to markets.
Sanofi-aventis is a leading global pharmaceutical company,
number 1 in Europe and in the BRIC-M (Brazil, Russia,
India, China and Mexico).
28 billion euros consolidated sales in 2007.
A growth built on a regional approach and
an extensive product portfolio.
Responses tailored to the local healthcare challenges:
Innovative medicines including eight international blockbusters
earning at least a billion euros in annual sales: Lovenox ® /Clexane ® ,
Plavix ® /Iscover ® , Lantus ® , Taxotere ® …
Mature prescription medicines
Reference treatments that are best adapted to local issues,
and medical and economic needs.
Consumer health products (OTC), Generics
Vaccines
Sanofi Pasteur is a world leader in the production
and commercialization of human vaccines.
Meeting the needs of countries in the Southern
hemisphere through «access to medicines» programs
to combat malaria, tuberculosis, sleeping sickness, leishmaniasis
and epilepsy.

Didier Robcis / Interlinks Image

Research inspired
by life
Innovation
in all
its dimensions.
Sanofi-aventis’ areas of therapeutic expertise:
Thrombosis, Cardiovascular Diseases, Diabetes, Vaccines, Oncology,
Central Nervous System Disorders and Internal Medicine.
Personalizing healthcare, by providing treatments for
all stages of disease to increase the comfort of patients
and improve their lives, using innovative technologies.
Sanofi-aventis explores new avenues of research and
forges partnerships, particularly in biotechnologies, to become
a precursor in the most innovative therapeutic areas.
47 products in advanced stages of research (Phase IIb/III).*
30 new products could be submitted for approval by the end
of 2010.
4.5 billion euros invested in R&D** in 2007.
*Figures taken from the portfolio of compounds and vaccines as
of 12 February 2008.
** R&D: Research and Development

Dung Vo Trung / Interlinks Image

Ethics in practice
Closer to local realities.
Committed to addressing the
human and economic challenges
facing today’s world.
Protecting the patient, ensuring our employees’ health
and safety, limiting the environmental impact of our activities.
Establishing widespread vaccination and developing medical
infrastructure in the poorest countries to eradicate
the bacterial and viral diseases that cause more
than 2 million deaths each year across the globe.
Responding to humanitarian emergencies and providing
lasting support for children, health and education.
Bringing together the skills and talents of sanofi-aventis
employees (R&D, Industrial Affairs, Pharmaceutical Operations)
to bolster the Group’s growth, dynamism and
creativity.

Forces for Life
Sanofi-aventis researches and develops
medicines and vaccines to improve the lives
of the greatest number of people.
Our R&D takes numerous innovative approaches
in the Group’s areas of therapeutic expertise:
Thrombosis, Cardiovascular Diseases, Diabetes, Vaccines, Oncology,
Central Nervous System Disorders and Internal Medicine.
The Company’s growth is built on a regional
approach backed by a comprehensive portfolio
of innovative medicines, mature prescription medicines, consumer
health products (OTC) and generics, as well as vaccines.
By virtue of its commitments, sanofi-aventis constantly adapts
its development model to the world’s emerging human and
economic problems.
www.sanofi-aventis.com
Corporate Communications - April 2008